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The goal of a drug delivery system is to achieve and sustain therapeutic blood 
levels of a drug. Various routes of administration are used in which, per-oral 
route is most preferred, being cost-effective and patient friendly. However per 
oral delivery presents many hurdles starting from drug dissolution in 
gastrointestinal (GIT) fluid to first pass metabolism and also due to various 
physicochemical and bio-pharmaceutical problems. With the result, oral 
therapy has limitations of large variability in the rate and extent of absorption 
of a therapeutic agent into the systemic circulation. 
Maximizing bioavailability of an orally administered drug is therapeutically 
important because the extent of bioavailability directly influences plasma 
concentrations, as well as therapeutic and toxic outcomes. Poorly bioavailable 
drugs are inefficient because a major portion of a dose never reaches the 
plasma or exerts its pharmacological effect. The inter-subject variability in 
bioavailability also remains correlated with the extent of bioavailability. 
Therefore low bioavailability leads to high variability and poor control of 
plasma concentration and effects. Inter-subject variability is particularly of 
concern for a drug with a narrow therapeutic margin or a steep dose vs. effect 
profile [1].  
Considerable evidence is accumulating to suggest that many clinically 
important anticancer drugs are not optimally utilized when taken orally. 
Majority of anticancer drugs show poor and variable bioavailability after their 
oral administration: many even with higher bioavailability show unpredictable 
variability [2, 3]. If systemic availability of a drug averages 20%, for example, 
then 80% of a dose is simply wasted. For drugs that are expensive to produce 
and beyond the reach of millions, wasting 80% of the precious substance is not 
comprehensible. There is, thus, a need to search for alternative drug forms 
having better action profile in terms of oral availability and efficacy.  
Since the beginning of its clinical development 40 years ago, etoposide has 
remained an important and widely used agent in clinical oncology. Its integral 
role in the treatment of germ cell tumors and small-cell lung cancer seems 
unlikely to diminish in the future, and its use in non-Hodgkin's lymphoma and 
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in various high dose regimens will probably continue to increase. Etoposide 
can be given using i.v. and oral formulations. The i.v. dose ranges from 100 to 
120 mg/m2, whereas the oral dose ranges from 200 to 240 mg/m2, reflecting the 
fact that etoposide has an oral bioavailability of ׽50%.  After oral 
administration, the absorption of etoposide is erratic and incomplete: both the 
rate and extent of absorption vary considerably among individuals, and even 
within the same individual, during chronic or multiple dosing, there is wide (25 
- 80%) intra-patient and inter-patient variability in systemic exposure and 
clearance [2, 4-12].      
Improving oral absorption and bioavailability of etoposide has therefore 
remained an important issue within the pharmaceutical industries. Investigation 
for newer active etoposide combination regimens continues for achieving 
improvement in its clinical activity with respect to its optimal dose and 
schedule.  
In recent times a new dimension in chemotherapeutics is being witnessed with 
regard to the development of drug enhancing technologies which will have 
revolutionary shift in the way medicines are administered. The global focus 
therefore is on newer approaches to reduce the drug dosage (and consequently 
cost), making treatment more affordable to a larger section of the society, along 
with lesser toxicity concerns.  
In this context herb-herb and herb-drug interactions have gained a major focus, 
with increasing trend towards the use and understanding of natural products as 
an alternative to the conventional treatment or as an additional medicine to 
boost the conventional therapy.  A vast literature is now available with respect 
to important pharmacokinetic interactions of wide variety of natural products 
(or their analogues) primarily derived from reputed medicinal herbs which 
have shown that such interactions could produce potential effect in vivo,  
among which drug bioavailability is one important pharmacological 
consequence [13,14].  
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In the recent past considerable research has been going on at CSIR- Indian 
Institute of Integrative Medicine (I.I.I.M.), Jammu in order to identify and 
develop bioenhancers which could effectively enhance the bioavailability of 
clinically important drugs which show poor bioavailability after oral 
administration. In this regard multiple bioenhancer moieties derived from 
natural (herbal) sources as well as their analogues have been investigated.  
During the last decade concerted research efforts have resulted in identifying 
an active alkaloid molecule piperine (1-piperoyl piperidine) from piper species, 
and also some other natural substances which have shown to increase the 
bioavailability of a large number of drugs and pharmaceutical agents, and other 
pharmacologically active substances (phenytoin, propranolol, theophylline, 
nevirapine, beta-lactam antibiotics, curcumin, coenzyme Q10, and 
epigallocatechin) in animals and human volunteers. A vast amount of 
information on the role of piperine as bioenhancer has been documented in 
many published reports [15-22]. The mode of bioenhancer action of piperine 
has been understood in its ability to influence the intestinal permeability, and a 
potential CYP 3A4/ P-gp inhibitory role [23-25]. 
In a significant development, CSIR-I.I.I.M., Jammu in public - private 
partnership with Cadila Pharmaceutical Ltd, Ahmedabad, has released a new 
drug formulation against tuberculosis called ‘risorine’, (containing a reduced 
dose of rifampicin along with isoniazid and piperine), which has been found to 
be bioequivalent to standard rifampicin regimen. Launched in November 2009, 
this indigenously developed drug formulation has been approved for marketing 
by Drug Controller General of India after successful completion of all the 
phased clinical trials.  
Recently a novel series of substituted piperine analogues have been synthesized 
at CSIR- IIIM, Jammu [26], and these analogues (including piperine) have 
been evaluated for identifying potential leads as enhancers of drug 
bioavailability with special emphasis on anti-cancer agents. During the 
preliminary investigations one such analogue namely, 4-ethyl 5-(3, 4-
methylenedioxyphenyl)-2E, 4E-pentadienoic acid piperidide, (PA-1) (Fig. 1) 
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was found to be a promising entity as bioavailability enhancer for the drug 
etoposide.   
 
Fig. 1: 4-Ethyl 5-(3, 4 methylenedioxyphenyl)-2E, 
4E - pentadienoic acid piperidine 
 
 
The present study deals with a detailed investigation on the pharmacokinetic 
interaction of PA-1 with etoposide in mice, which has resulted in a significant 
enhancement of bioavailability of orally, administered etoposide. A 
mechanistic evaluation has also been undertaken to examine the mode of action 
of PA-1 by studying some key biochemical events such as absorption/ efflux, 
and metabolism of this drug, as influenced by P-glycoprotein (P-gp), and 
selected cytochrome P450 (CYP) enzymes, which are now recognized as major 
regulators of oral drug bioavailability. 
 
